StockIQ.techBridgeBio Pharma, Inc. (BBIO) Stock Analysis
Free AI-powered analysis and research for BridgeBio Pharma, Inc. stock
Sector: Healthcare
BBIO snapshot
Data as of 3 Nov 2026 close. Updated daily.
BridgeBio Pharma, Inc. scores 59/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 43% of its 52-week range, up 20.2% over the past year. Latest reported figures show a profit margin of -97.0% and revenue growth of +120.4%.
What is driving the score
- Mixed Trend: +0
- MACD Bullish: +8
- Strong Revenue Growth (120.4%): +8
- Unprofitable (-97.0%): -15
- Weak Liquidity (1.23 Current Ratio): -5
- Low P/B (-5.48): +5
- Above MA200: +4
- Healthy Momentum (+20.2% over 1 year): +7
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BBIO report
BridgeBio Pharma, Inc. (BBIO) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BBIO Now →📰 Latest Update
What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?
Sun, November 1, 2026 at 9:10 PM UTC 3 min read
BridgeBio Pharma (NasdaqGS:BBIO) plans to launch three products currently under FDA priority review within the next seven months, aiming for corporate breakeven and brand-level profitability by 2028. The FDA's priority review of infigratinib for achondroplasia underscores the company's focus on its rare disease pipeline. However, the article highlights concerns about BridgeBio's reliance on a single therapy and ongoing losses, which could be exacerbated by competition from larger players in the rare disease market.